Chronic hyperinsulinemia inhibits platelet-activating factor (PAF) biosynthesis in the rat kidney.

[1]  M. Jones,et al.  Differential metabolism of exogenous platelet-activating factor by glandular epithelial and stromal cells of rabbit endometrium. , 1995, Journal of reproduction and fertility.

[2]  M. Harper,et al.  Lyso-PAF:acetyl-CoA acetyltransferase and CDP-choline cholinephosphotransferase activities in the rabbit endometrium. , 1995, Journal of lipid mediators and cell signalling.

[3]  R. DeFronzo,et al.  The Metabolic Profile of NIDDM Is Fully Established in Glucose-Tolerant Offspring of Two Mexican-American NIDDM Parents , 1992, Diabetes.

[4]  S. Haffner,et al.  Prospective Analysis of The Insulin-Resistance Syndrome (Syndrome X) , 1992, Diabetes.

[5]  D. Martin,et al.  Cardiovascular Responses to Bicuculline in the Paraventricular Nucleus of the Rat , 1991, Hypertension.

[6]  M. Frölich,et al.  Whole body and hepatic insulin action in normal, starved, and diabetic rats. , 1991, The American journal of physiology.

[7]  F. Snyder,et al.  A coenzyme A-independent transacylase is linked to the formation of platelet-activating factor (PAF) by generating the lyso-PAF intermediate in the remodeling pathway. , 1991, The Journal of biological chemistry.

[8]  R. DeFronzo,et al.  Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.

[9]  K. Waku,et al.  Ether lysophospholipid-induced production of platelet-activating factor in human polymorphonuclear leukocytes. , 1990, Biochimica et biophysica acta.

[10]  F. Snyder.  Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. , 1990, The American journal of physiology.

[11]  S. Haffner,et al.  Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? , 1990, JAMA.

[12]  F. Snyder,et al.  Characterization of the enzymatic hydrolysis of acetate from alkylacetylglycerols in the de novo pathway of PAF biosynthesis. , 1990, Biochimica et biophysica acta.

[13]  M. Harper,et al.  Characterization of platelet-activating factor binding sites on uterine membranes from pregnant rabbits. , 1989, Biology of reproduction.

[14]  T. Imaizumi,et al.  Increased activity of the platelet-activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertension. , 1989, Prostaglandins.

[15]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[16]  F. Snyder,et al.  Stimulation of the de novo pathway for the biosynthesis of platelet-activating factor (PAF) via cytidylyltransferase activation in cells with minimal endogenous PAF production. , 1988, The Journal of biological chemistry.

[17]  R. Vandongen,et al.  Increased levels of platelet-activating factor (1-O-alkyl-2-acetylglycerophosphocholine) in blood after reversal of renal clip hypertension in the rat. , 1988, Clinical science.

[18]  F. Snyder,et al.  Formation of 1-alkyl-2-acetyl-sn-glycerols via the de novo biosynthetic pathway for platelet-activating factor. Characterization of 1-alkyl-2-acetyl-sn-glycero-3-phosphate phosphohydrolase in rat spleens. , 1988, The Journal of biological chemistry.

[19]  D. Stafforini,et al.  Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. , 1987, The Journal of biological chemistry.

[20]  F. Snyder,et al.  The final step in the de novo biosynthesis of platelet-activating factor. Properties of a unique CDP-choline:1-alkyl-2-acetyl-sn-glycerol choline-phosphotransferase in microsomes from the renal inner medulla of rats. , 1987, The Journal of biological chemistry.

[21]  F. Snyder,et al.  A new de novo pathway for the formation of 1-alkyl-2-acetyl-sn-glycerols, precursors of platelet activating factor. Biochemical characterization of 1-alkyl-2-lyso-sn-glycero-3-P:acetyl-CoA acetyltransferase in rat spleen. , 1986, The Journal of biological chemistry.

[22]  F. Snyder,et al.  Acylation of lysophospholipids by rabbit alveolar macrophages. Specificities of CoA-dependent and CoA-independent reactions. , 1985, The Journal of biological chemistry.

[23]  R. Kramer,et al.  Metabolism of platelet-activating factor in human platelets. Transacylase-mediated synthesis of 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine. , 1984, The Journal of biological chemistry.

[24]  A. Wissner,et al.  Hypotensive and vasodilatory activity of (+/-) 1-o-octadecyl-2-acetyl glyceryl-3-phosphorylcholine in the normotensive rat. , 1983, Life sciences.

[25]  L. W. Byers,et al.  Cardiovascular Effects of Antihypertensive Polar and Neutral Renomedullary Lipids , 1983, Hypertension.

[26]  F. Snyder,et al.  Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor and a hypotensive lipid) by cholinephosphotransferase in various rat tissues. , 1981, Biochimica et biophysica acta.

[27]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[28]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.